While Alzheimer’s drugs may offer some benefits, Medicare must consider the financial burden these expensive treatments place on taxpayers. The program should focus on cost-effective strategies and ensure resources are allocated to various healthcare needs rather than disproportionately funding high-cost medications with uncertain effectiveness.